A user shared their positive progress with denser hair after one year on finasteride, considering adding oral minoxidil. They experienced no side effects and gained confidence.
The conversation discusses the possibility of transplanting leg and arm hair to the scalp for hair loss treatment. Minoxidil is mentioned as a potential aid for hair growth, but concerns about the effectiveness and appearance of body hair on the head are raised.
Dutasteride takes 1-3 months to affect scalp DHT levels, not just a week. The prostate absorbs Dutasteride faster than the scalp due to different vascular networks and enzyme densities.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
The conversation discusses the severe shedding caused by Minoxidil, with users sharing their experiences and outcomes. Some report eventual regrowth, while others see no improvement or worsening hair loss.
A user is excited to start using Pyriltamide for hair loss after experiencing side effects from topical finasteride. Other users discuss the potential and skepticism of Pyriltamide compared to older treatments like finasteride and RU58841.
A 40+ male shared his one-year progress using minoxidil twice daily and microneedling once a week, showing significant hair improvement. He also occasionally uses finasteride in a low dosage due to side effects.
A user reported that Procerin, containing Saw Palmetto and Pumpkin seed oil, provided similar hair thickening results as finasteride but with milder side effects. They experienced reduced libido and watery ejaculations but are adjusting the dose to minimize these effects.
A 19-year-old is distressed about his 17-year-old autistic brother's hair loss, projecting his own insecurities despite being on finasteride and dutasteride. Replies suggest the brother might not care about balding, and the poster should address his own issues.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.